Regal Cancer Trial Nears Critical Analysis Milestone
The study reaches 78 of 80 deaths required to trigger a final review of treatment efficacy for patients.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Is now a good time for individual investors to buy stocks based on potential regulatory approvals?
Sellas Life Sciences Group is nearing a critical data milestone for its Regal trial, which has recorded 78 of the 80 required deaths needed to trigger a final analysis. This progress, alongside ongoing studies for the treatment SLS009, signals a pivotal development phase for patients monitoring potential new cancer therapy options.
Why it matters
The completion of the Regal trial analysis is a necessary step for evaluating the efficacy of GPS, a cancer therapy currently tracking toward potential 2027 regulatory milestones in Europe. For patients, these findings provide essential data on whether the treatment effectively alters clinical outcomes.
The Regal trial has reached 78 deaths as of May 11, 2026, out of the 80 required to trigger a final database lock, review, and unblinding. Final analysis will determine whether the therapeutic intervention meets its primary study endpoints.
The players
Sellas Life Sciences Group
A biopharmaceutical company focused on developing novel cancer immunotherapies and treatments for hematologic and solid tumors.
BlackRock
A global investment management firm that monitors corporate performance and holds equity across the healthcare and life sciences sectors.
The details
The Regal trial assesses the clinical efficacy of GPS by monitoring participant mortality until a pre-specified threshold of 80 events is met. Once this threshold is reached, researchers proceed with unblinding the treatment and control groups to evaluate if the drug significantly impacts patient survival compared to the standard of care. Concurrently, the company is evaluating the safety and efficacy of the pipeline drug SLS009, which recently moved through a 28-patient Phase 2 study.
Timeline
March 2026: BlackRock held 12.14 million shares of Sellas Life Sciences.
May 11, 2026: The Regal trial reached 78 recorded deaths.
September 30, 2026: BlackRock's ownership increased to 15.87 million shares.
Q4 2026: Sellas expects topline results from its SLS009 Phase 2 study.
2027: Potential European regulatory approval or registration for GPS.
Health Landscape
The clinical progression of GPS sits within a broader European regulatory framework, where tools like the Dutch Medicines Horizon Scan help health systems anticipate new drug availability. This approach standardizes how clinicians and administrators prepare for emerging therapies as they move from Phase 3 trials to potential market registration.
Patients tracking new developments in cancer care should monitor future announcements regarding the Regal trial's final analysis, as these results will influence treatment availability. It is a topic worth discussing with an oncologist to understand how emerging trial data might relate to current therapeutic options.
The takeaway
The transition of a drug through Phase 3 trials and toward regulatory review is a multi-year process that requires clear safety and efficacy data. Patients interested in clinical advancements should follow trial registries for updates on data release milestones, as these reports determine if a drug reaches the clinic.
What happens next
Sellas expects to release topline results from its Phase 2 study of SLS009 in the fourth quarter of 2026, while the 80th event in the Regal trial will trigger the final database lock.
Further reading
For more information on the current landscape of oncology research and trial progression, visit Cancer.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Is now a good time for individual investors to buy stocks based on potential regulatory approvals?
